CryoCath Looks To Ice Atrial Fibrillation, Flutter With Cryoablation Therapies
This article was originally published in The Gray Sheet
Executive Summary
CryoCath aims to place its Freezor cryoablation catheter in 300 centers by year-end, pending PMA approval of the supraventricular tachycardia treatment device
You may also be interested in...
CryoCath Freezor Tachycardia Approval Includes Cryomapping Indication
CryoCath says it will pursue an expanded indication for its Freezor cardiac cryoablation system to address epicardial posteroseptal accessory atrioventricular pathways
CryoCath Freezor Tachycardia Approval Includes Cryomapping Indication
CryoCath says it will pursue an expanded indication for its Freezor cardiac cryoablation system to address epicardial posteroseptal accessory atrioventricular pathways
Ablation assets
CryoCath inks $10 mil. deal to acquire Endocare's cardiac-related product manufacturing operations in Irvine, Calif. The sale is subject to Endocare's clearing certain manufacturing and R&D milestones in 2003. Terms include the exclusive licensing of the Surgifrost cryoablation system to CryoCath in exchange for a nine-year descending royalty stream based on net sales. The deal represents the latest move by Endocare to divest non-core assets to concentrate resources on its Cryocare prostate cancer platform (1"The Gray Sheet" April 14, 2003, p. 27). SurgiFrost was developed through a partnership between the two companies and was approved to treat cardiac arrhythmias in February 2002 (2"The Gray Sheet" Feb. 3, 2003, p. 20)...